India AMC Stocks 2026: HDFC AMC, Nippon Life & UTI — ROCE, Margins & Valuations

India's mutual fund industry crossed ₹65 lakh crore in assets under management (AUM) in 2026, driven by a decade of SIP culture, rising retail equity participation, and a structural shift from physical savings (gold, fixed deposits) to financial assets. The three listed asset management companies — HDFC AMC, Nippon Life AMC (NSE: NAM-INDIA), and UTI AMC — are the direct beneficiaries of this structural tailwind. Yet the quality gap between them is significant, and the market prices each one very differently.

We pulled live FY26 annual data from the DocStoX dataset (sourced from NSE/BSE audited annual filings) for all three stocks and ranked them by ROCE, EBITDA margin, and ROE — the three metrics that determine long-term value creation in an asset-light, fee-based business like fund management. These are not TTM estimates or modelled projections. Every figure here is from the audited annual (FY26) row, as of 10 July 2026.

Why AMC Stocks Are Structurally Different

Asset management is one of the few genuinely capital-light businesses in Indian financial services. Unlike banks (which carry credit risk and capital adequacy constraints) or NBFCs (which need balance-sheet leverage to earn returns), an AMC earns management fees as a percentage of AUM — with near-zero incremental capital deployed as AUM grows. This is why HDFC AMC runs an 83% EBITDA margin: every additional rupee of AUM flows almost entirely to the operating profit line once fixed infrastructure costs are covered.

The flip side: in a market downturn, AUM compresses (mark-to-market losses reduce the fee base), and revenue can fall sharply without a commensurate cost reduction. The business is highly correlated to equity market performance. For investors analysing India AMC stocks 2026, the core question is: which AMC is best positioned to grow AUM profitably — and at what valuation are you paying for that growth?

ROCE Rankings: The FY26 Scoreboard (10 July 2026)

All figures are from NSE/BSE audited annual filings (FY26, March 2026 period), pulled from the DocStoX dataset:

• Nippon Life AMC (NAM-INDIA): 44% ROCE — highest in the group, ROE 34.5%, PAT margin 52.3%
• HDFC AMC (HDFCAMC): 43% ROCE — near-identical ROCE to Nippon, 83% EBITDA margin, ROE 31%
• UTI AMC (UTIAMC): 16% ROCE — materially lower, ROE 10.3%, but highest dividend yield at 4.07%

The ROCE gap between the top two (44%/43%) and UTI (16%) is the central quality divide in this sector. HDFC AMC and Nippon Life AMC operate with structurally higher profitability — reflecting better fund performance track records, larger equity-oriented AUM mixes (which carry higher fees than debt funds), and more efficient distribution costs. UTI AMC carries legacy cost structures and a higher share of lower-margin institutional/debt AUM.

Nippon Life AMC (NAM-INDIA): Highest ROCE, Near Its 52-Week High

Nippon Life AMC is the standout quality-returns story in this analysis. At 44% ROCE and ROE of 34.5% — both the highest in the group — it combines exceptional capital efficiency with a growing equity AUM franchise. Revenue of ₹2,924 crore, PAT of ₹1,529 crore (PAT margin 52.3%), and EBITDA of ₹2,010 crore at a 69% EBITDA margin underline a business firing on all cylinders.

The balance sheet is virtually debt-free (D/E 0.02). Market cap stands at ₹77,402 crore. At a PE of 50.59x, the stock is priced at a premium — the market assigns Nippon a higher multiple than HDFC AMC despite the latter's larger scale. This likely reflects Nippon's superior ROE and the perception that it has more runway to grow its equity AUM market share relative to the sector leader. The current price of ₹1,212.7 is within 1.7% of its 52-week high of ₹1,233.5 — practically at peak. Dividend yield: 1.77%.

HDFC AMC (HDFCAMC): 83% EBITDA Margin — One of the Highest in Indian Equities

HDFC AMC's 83% EBITDA margin deserves a moment of context: in Indian large-cap equities, an 83% EBITDA margin is extraordinarily rare. Software companies achieve 35-40%; the best pharma names reach 33%. HDFC AMC, as India's largest mutual fund by AUM, has crossed the scale threshold where operating leverage has made virtually every additional rupee of revenue flow directly to EBITDA. Revenue of ₹4,050 crore converts to PAT of ₹2,461 crore — a PAT margin of 60.8% and EBITDA of ₹3,346 crore.

ROCE of 43%, ROE of 31%, and a completely debt-free balance sheet (D/E 0.0) make HDFC AMC one of India's highest-quality businesses. The catch is valuation: at PE 47.98x and market cap of ₹1,18,266 crore (~₹1.18 lakh crore), it is already extensively priced. The current price of ₹2,761.2 is down 53% from its 52-week high of ₹5,934.5 and up 28% from its 52-week low of ₹2,158.4 — the large 52-week range reflecting a significant de-rating event (likely regulatory fee-cap pressures or a broader financial-sector selloff). Dividend yield: 1.94%.

UTI AMC (UTIAMC): Value, Dividend Yield, But Structurally Lower Returns

UTI AMC is the value-and-income play in this group. At PE 31.94x — the cheapest of the three — and a dividend yield of 4.07% (the highest of the three by a significant margin), it offers income-oriented investors a combination that HDFC AMC and Nippon do not. Revenue of ₹1,705 crore, PAT of ₹472 crore (PAT margin 27.7%), and EBITDA of ₹816 crore at a 48% EBITDA margin reflect a smaller, more cost-burdened operation.

ROCE of 16% and ROE of 10.3% are the group lows — a meaningful gap from Nippon (44% ROCE) and HDFC AMC (43% ROCE). The low D/E of 0.03 is a positive, and the market cap of ₹12,912 crore makes it the smallest of the three by a wide margin. Current price of ₹1,004.3 is down 32.8% from its 52-week high of ₹1,494.8 but up 12% from its 52-week low of ₹896.5 — suggesting the stock is recovering from a de-rating but has not yet regained its highs. UTI AMC's lower ROCE reflects a legacy of higher institutional/debt-fund AUM, government-mandated obligations, and a less aggressive equity-distribution push compared to peers.

FY26 Profitability: The Full Scoreboard

All figures are from NSE/BSE audited annual filings (FY26, March 2026 period), sourced via DocStoX data (as of 10 July 2026):

• HDFC AMC: Revenue ₹4,050 Cr | PAT ₹2,461 Cr | PAT Margin 60.8% | EBITDA Margin 83% | ROCE 43% | ROE 31% | D/E 0.0 | P/E 47.98x | Mkt Cap ₹1.18 lakh Cr | Div Yield 1.94%
• Nippon Life AMC: Revenue ₹2,924 Cr | PAT ₹1,529 Cr | PAT Margin 52.3% | EBITDA Margin 69% | ROCE 44% | ROE 34.5% | D/E 0.02 | P/E 50.59x | Mkt Cap ₹77,402 Cr | Div Yield 1.77%
• UTI AMC: Revenue ₹1,705 Cr | PAT ₹472 Cr | PAT Margin 27.7% | EBITDA Margin 48% | ROCE 16% | ROE 10.3% | D/E 0.03 | P/E 31.94x | Mkt Cap ₹12,912 Cr | Div Yield 4.07%

The most striking finding: Nippon Life AMC's PAT margin of 52.3% and ROCE of 44% fractionally exceed HDFC AMC's on a per-rupee basis — yet HDFC AMC generates 1.6x Nippon's absolute PAT on 1.4x the revenue, reflecting the significant scale advantage of being India's largest fund house. The PAT-to-ROCE comparison between the two illustrates a classic quality-at-scale versus quality-at-growth debate in India AMC stocks 2026.

Catalysts to Watch in H2 FY27

1. SIP inflow trajectory: Monthly SIP inflows are the most watched metric for India's AMC sector. Sustained SIP growth above ₹25,000 crore/month is the structural AUM driver for all three companies. Any deceleration in SIP registrations — typically triggered by equity market volatility — compresses the fee base. Any acceleration re-rates the entire sector upward.
2. SEBI fee-cap regulations: SEBI periodically reviews total expense ratio (TER) ceilings for mutual funds. Any downward revision to TER caps — which directly reduce the management fee percentage that AMCs can charge — would be a margin headwind, particularly for HDFC AMC whose operating leverage makes it the most fee-sensitive. This is a key regulatory risk to monitor.
3. Equity market performance: AMC AUM is mark-to-market. A 10% rally in Nifty 50 translates to ~10% AUM growth (and commensurate fee revenue growth) even with zero net new inflows. In FY27, the direction of the Indian equity market is the single largest external variable for AMC earnings.
4. Nippon's market-share gains: Nippon Life AMC has been gaining retail equity AUM market share from legacy players including UTI. Any acceleration in this trend — measurable via monthly AMFI AUM disclosures — would justify Nippon's premium PE relative to HDFC AMC.
5. UTI AMC's equity AUM mix shift: UTI's structural de-rating stems from its higher proportion of debt/institutional AUM (lower fees) vs equity AUM. Any structural shift in UTI's product mix toward equity — driven by new fund launches or improved fund performance — would be the key re-rating catalyst for the cheapest stock in this group.

The DocStoX Take

India's three listed AMC stocks in 2026 split into two distinct profiles:

Quality compounders (HDFC AMC and Nippon Life AMC): Both run 43-44% ROCE, are near-debt-free, and deliver PAT margins above 50%. The differentiation between them is scale (HDFC AMC) vs returns momentum (Nippon Life AMC — higher ROE at 34.5% vs 31%). Both trade at premium PEs (48x and 51x) that reflect the market's confidence in India's long-term SIP-driven AUM growth story. For long-term investors who believe in the structural financialisation of Indian savings, these are the two names to track — the question is timing relative to equity market cycles and SEBI regulatory events.

Value/income (UTI AMC): At 32x PE, 16% ROCE, and a 4.07% dividend yield, UTI AMC offers income investors an above-average yield in a sector where peers yield under 2%. The structural ROE gap (10.3% vs 31-34%) is real and reflects genuine operational underperformance — not temporary cyclicality. A UTI AMC re-rating requires either a market-share recovery in equity AUM or a material cost-efficiency improvement. Until one materialises, the valuation discount to peers is largely justified.

For investors screening India AMC stocks 2026 on quality-adjusted-returns, Nippon Life AMC's 44% ROCE leadership at a near-52W-high price — and HDFC AMC's 83% EBITDA margin as a structural quality indicator — are the two data points this analysis surfaces. Full live data, DocStoX AI verdicts, and fair-value estimates for HDFC AMC, Nippon Life AMC, and UTI AMC are available at docstox.com.

---

By the DocStoX Desk — This is for informational purposes only and not investment advice. Please consult a SEBI-registered advisor before investing.